Diabetes pp 42-50 | Cite as

Type 2 Diabetes Mellitus, Pandemic in 21st Century

  • Emil GinterEmail author
  • Vlado Simko
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 771)


In the second half of the 20th century it became obvious that a relentless increase in Type 2 diabetes mellitus (T2DM), affecting the economically affluent countries, is gradually afflicting also the developing world. This chapter shows the threat that the T2DM epidemic represents to mankind, with the astonishing recent discoveries on the role of obesity and of body fat in this metabolic disorder. Presently, the highest prevalence of T2DM is in Saudi Arabia. T2DM is very high in over 10% of adults in the USA, Switzerland and Austria. Prevalence is low in Norway, China and in Iceland. Predictions of epidemiologists for the first third of the 21st century claim up to 2.5 times increase in the prevalence of T2DM in the Middle East, Sub-Saharan Africa, India, rest of Asia and in the Latin America. In China the number of patients with T2DM will double in 2030. In the economically advanced countries the increase will be about 50% in 2030.

Increasing urbanization, aging populations, obesity and falling levels of physical activity are all contributing to the rise of T2DM worldwide. The main cause of T2DM pandemic is growing prevalence of obesity in Europe and USA. In the North America and European Union countries obesity is considered to be responsible for up to 70–90% of T2DM in adult population. The precise mechanism by which obesity leads to insulin resistance and to T2DM is not completely known but it may be related to several biochemical factors such as abnormalities in free fatty acids, adipokines, leptin and other substances.


Insulin Resistance Free Fatty Acid Brown Adipose Tissue Curr Opin Investig Drug Brain Insulin Resistance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Diabetes Atlas, International Diabetes federation, USA, 2007.Google Scholar
  2. 2.
    Roglic G, Green A et al. Prevalence of diabetes. Estimates for the year 2000 and projection for 2030. Diabetes Care 2004; 27:1047–1053.CrossRefPubMedGoogle Scholar
  3. 3.
    WHO. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Geneva, Switzerland, 2009.Google Scholar
  4. 4.
    CDC. Centres for Disease Control and Prevention. Atlanta, USA, 2007.Google Scholar
  5. 5.
    James WPT, Jackson-leach R, Mhurdu CN et al. Overweight and obesity. In: Ezzati M, Lopez AD, Rodgers A et al, eds. Comparative Quantification of Health Risks. WHO, Geneva, 2003.Google Scholar
  6. 6.
    Basdevant A, Ciangura C. Obesity, a disease. Bull Acad Natl Med 2010; 194(10):13–20.PubMedGoogle Scholar
  7. 7.
    Hummasti S, Hotamisligil GS. Endoplasmic reticulum stress and inflammation in obesity and diabetes. Circ Res 2010; 107(5):579–591.CrossRefPubMedGoogle Scholar
  8. 8.
    Boden G. Obesity and free fatty acids. Endocrinol Metab clin North Amer 2008; 37(3):635–646.CrossRefGoogle Scholar
  9. 9.
    Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr Diab rep 2006; 6(sn3):177–181.CrossRefPubMedGoogle Scholar
  10. 10.
    Wilding JP. The importance of free fatty acids in the development of type 2 diabetes. Diabet Med 2007; 24(9):934–945.CrossRefPubMedGoogle Scholar
  11. 11.
    Ioannidis I. The road from obesity to type 2 diabetes. angiology 2008; 59(2 Suppl):39S–43S.CrossRefPubMedGoogle Scholar
  12. 12.
    lele RD. Pro-insulin, C peptide, glucagon, adiponectin, TNF alpha, AMPK: neglected players in type 2 diabetes mellitus. J Assoc Physicians India 2010; 58:35–40.Google Scholar
  13. 13.
    Rasouli N, kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93(11 Suppl 1):S64–S73.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    keller U. From obesity to diabetes. Int J Vitam Nutr res 2006; 76(4): 172–177.CrossRefPubMedGoogle Scholar
  15. 15.
    Dardeno TA, Chou SH, Moon HS et al. Leptin in human physiology and therapeutics. Front Neuroendocrinol 2010; 31(3):377–393.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Viollet B, Lantier L, Devin-Leclerc J et al. Targeting the AMPK pathway for the treatment of type 2 diabetes. Front Biosci 2009; 14:3380–3400.CrossRefGoogle Scholar
  17. 17.
    Long YC, Zierath JR. AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 2006; 116(7):1776–1783.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Hardie DG. AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes2008;32Suppl 4:S712.Google Scholar
  19. 19.
    Christian M, Parker MG. the engineering of brown fat. J Molec cell Biol 2010; 2(1):23-25.CrossRefGoogle Scholar
  20. 20.
    Ginter E, Simko V. adult obesity at the beginning of the 21st century: epidemiology, pathophysiology and health risk. Bratisl Lek Listy 2008; 109(5):224–230.PubMedGoogle Scholar
  21. 21.
    Cypess AM, Lehman S, Williams G et al. Identification and importance of brown adipose tissue in adult humans. New Eng J Med 2009; 360:1509–1517.CrossRefPubMedGoogle Scholar
  22. 22.
    De la Monte SM, Longato L, Tong M et al. Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. curr opin Investig Drugs 2009; 10(10):1049–1060.Google Scholar
  23. 23.
    Daniels SR, Jacobson MS, Mccrindle BW et al. American heart association childhood obesity research Summit: executive summary. Circulation 2009; 119(15):2114–2123.CrossRefPubMedGoogle Scholar
  24. 24.
    Gordon-larsen P, Boone-Heinon J, Sidney S et al. Active commuting and cardiovascular disease risk. the CARDIA study. Arch Intern Med 2009; 169:1216–1223.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Ferencik M, Hulin I. Obesity, fatty tissue and inflammation. Med Monitor 2008; 4:16.Google Scholar
  26. 26.
    Mudaliar S, henry RR. Incretin therapies: Effects beyond glycemic control. am J Med 2009; 122:S25–S36.CrossRefPubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2013

Authors and Affiliations

  1. 1.Institute of Preventive and Clinical Medicine (IPCM)BratislavaSlovakia
  2. 2.Downstate Medical Center at BrooklynState University of New YorkBrooklynUSA

Personalised recommendations